Skip to content
About CombiGene
Projects
The pain program COZY
The epilepsy project CG01
The lipodystrophy project CGT2
Patent
The Market
Organization
Investors
Financial reports
Prospectus/IM
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association
Company description
IR-contact
Certified Adviser
Media
Press releases
Presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
About CombiGene
Projects
The pain program COZY
The epilepsy project CG01
The lipodystrophy project CGT2
Patent
The Market
Organization
Investors
Financial reports
Prospectus/IM
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association
Company description
IR-contact
Certified Adviser
Media
Press releases
Presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
SV
Interview Jan Nilsson, CEO CombiGene (In Swedish)
September 4, 2017
Share
News
September 15, 2023
CombiGene chooses CDMO partner for the COZY01 pain project
September 8, 2023
New issue of Ingeneious, no 4 2023
September 5, 2023
Epilepsy Project CGO1 progressing through optimization activities in preparation for in-human studies
August 25, 2023
Interim report January – June 2023 for CombiGene AB (publ)
June 30, 2023
Jan Nilsson leaves his position as CEO of CombiGene – COO Peter Ekolind takes over as new CEO on September 1, 2023
June 29, 2023
CombiGene forms prominent Scientific Advisory Board within the pain program COZY
June 28, 2023
New issue of Ingeneious, no 3 2023
May 25, 2023
Bulletin from the annual general meeting of CombiGene AB (publ)
Load more
